Abstract
We studied Basal-plus therapy effectiveness with the new rapid-acting insulin analog insulin glulisine. Subjects were 17 persons with type 2 diabetes and poor HbA1c levels undergoing basal-supported oral therapy (BOT) . Subjects were administered added insulin glulisine at the evening meal. After 12 weeks of treatment, the insulin glulisine dosage was 4.8 ±1.4 unit. HbA1c decreased significantly at 7.4 ±0.8% to 7.0 ±0.7%, P<0.001, while BMI (23.1 ±3.7 to 23.2 ±3.4 kg/m2, P=0.839) and hypoglycemia frequency (1.2 ±3.0 to 0.9 ±1.4 times/month, P=0.729) did not change significantly. We evaluated quality of life (QOL) with the insulin-therapy-related QOL measure questionnaire (ITR-QOL) . After 12 weeks, the number of insulin injections increased, but ITR-QOL did not worsen significantly (99.2 ±12.1 to 97.1 ±15.4, P=0.331) . These results suggest that basal-plus therapy with insulin glulisine aids in glycemic control and QOL in those with type 2 diabetes.
